Biocircuits Corp., of Sunnyvale, Calif., received FDAclearance for a T4 assay and a combined T4 and T uptakeassay for its IOS immunodiagnostic testing system. Thesystem's first two assays assess thyroid function.
BioStar Inc., of Boulder, Colo., received FDA clearanceto market its Optical ImmunoAssay chlamydia point-of-care test.
Cytogen Corp., of Princeton, N.J., received FDAapproval for repeat administration for its cancer imagingagent, OncoScint CR/OV. The original 1992 approvalwas for single administration only.
Sonus Pharmaceuticals, of Bothell, Wash., said itcompleted enrollment in its Phase III trial of EchoGenEmulsion for use as an ultrasound contrast agent. Resultshave not been analyzed.
Metra Biosystems Inc., of Mountain View, Calif., andWyeth-Ayerst Laboratories, of Radnor, Pa., initiated anon-exclusive worldwide co-promotion collaborationrelated to the company's products to diagnose, treat andprevent osteoporosis. Among the products involved areMetra's recently approved Pyrilinks assay, whichmeasures bone collagen loss, and Wyeth-Ayerst'sestrogen products. Initially, the plan is to increaseeducation and awareness of bone disorders.
(c) 1997 American Health Consultants. All rights reserved.